These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24966972)

  • 1. Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Zhou C; Wang R; Ding Y; Du L; Hou C; Lu D; Hao L; Lv W
    Int J Clin Exp Pathol; 2014; 7(5):2579-86. PubMed ID: 24966972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: a prospective cohort study.
    Hao JF; Zhang LW; Bai JX; Li YJ; Liu JN; Zhang XL; Han JM; Li X; Jiang H; Cao N
    Indian J Cancer; 2015 Feb; 51 Suppl 2():e3-8. PubMed ID: 25712839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Sohn W; Ham CB; Kim NH; Kim HJ; Cho YK; Jeon WK; Kim BI
    PLoS One; 2020; 15(12):e0243780. PubMed ID: 33315944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.
    Lee BC; Liu KL; Lin CL; Kao CH
    Eur Radiol; 2017 Nov; 27(11):4482-4489. PubMed ID: 28593432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
    Boulin M; Adam H; Guiu B; Aho LS; Cercueil JP; Di Martino C; Fagnoni P; Minello A; Jouve JL; Hillon P; Bedenne L; Lepage C
    Dig Liver Dis; 2014 Apr; 46(4):358-62. PubMed ID: 24462550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
    Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
    Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
    Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
    World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute kidney injury after transarterial chemoembolization for hepatocellular carcinoma: a retrospective analysis.
    Park J; Chung HC; Lee JS; Lee BM; Kim DM; Hwang JC; Jo MW; Noh M; Shin JW
    Blood Purif; 2008; 26(5):454-9. PubMed ID: 18810227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and Management of Acute Kidney Injury in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization.
    Hong CX; Lv LW; Hua LZ; Bo S; Sen CX; Xin NY; Wei YJ; Rui XJ; Qiang DX; Zhou ZJ
    Curr Protein Pept Sci; 2017; 18(12):1218-1223. PubMed ID: 27634445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.
    Aoe M; Kanemitsu T; Ohki T; Kishi S; Ogura Y; Takenaka Y; Hashiba T; Ambe H; Furukawa E; Kurata Y; Ichikawa M; Ohara K; Honda T; Furuse S; Saito K; Toda N; Mise N
    Clin Exp Nephrol; 2019 Sep; 23(9):1141-1146. PubMed ID: 31183589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
    Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
    Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
    Li J; Shi C; Shi J; Song J; Wang N
    Medicine (Baltimore); 2021 Nov; 100(44):e27636. PubMed ID: 34871232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Jang BK; Lee SH; Chung WJ; Park KS; Cho KB; Hwang JS; Kim YH; Choi JS; Kwon JH
    Korean J Hepatol; 2008 Jun; 14(2):168-77. PubMed ID: 18617764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.